214 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
27391135	28	3-Hydrazinoindolin-2-one derivatives: Chemical classification and investigation of their targets as anticancer agents.	Egyptian Russian University
27171036	164	Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy.	University of Nebraska Medical Center
27363938	2	A chromatography-free isolation of rohitukine from leaves of Dysoxylum binectariferum: Evaluation for in vitro cytotoxicity, Cdk inhibition and physicochemical properties.	India Academy of Scientific & Innovative Research (Acsir)
27297568	50	Benzamide capped peptidomimetics as non-ATP competitive inhibitors of CDK2 using the REPLACE strategy.	University of South Carolina
27055065	92	Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle Kinase 1 (MPS1) Using a Structure-Based Hybridization Approach.	The Institute of Cancer Research
27089211	38	Design, synthesis and biological evaluation of pyrazol-furan carboxamide analogues as novel Akt kinase inhibitors.	Zhejiang University
27003761	120	Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.	Nerviano Medical Sciences
27117263	51	Discovery and optimization of 1,7-disubstituted-2,2-dimethyl-2,3-dihydroquinazolin-4(1H)-ones as potent and selective PKC¿ inhibitors.	Takeda Pharmaceutical
26762835	342	Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2).	Icahn School of Medicine At Mount Sinai
26408454	51	An integrated approach for discovery of highly potent and selective Mnk inhibitors: Screening, synthesis and SAR analysis.	University of South Australia
26222319	192	Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy.	Nerviano Medical Sciences
26115571	38	Cyclin dependent kinase (CDK) inhibitors as anticancer drugs.	Eli Lilly
25007344	73	Optimization of potent DFG-in inhibitors of platelet derived growth factor receptorß (PDGF-Rß) guided by water thermodynamics.	Christian-Albrechts-University of Kiel
26071372	89	Synthesis and evaluation of novel 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives as potent and orally efficacious immunomodulators targeting JAK3.	Astellas Pharma
25454794	1	Iterative conversion of cyclin binding groove peptides into druglike CDK inhibitors with antitumor activity.	University of South Carolina
24798019	30	Acridone alkaloids from Glycosmis chlorosperma as DYRK1A inhibitors.	Institut De Chimie Des Substances Naturelles
25010935	1	Design and synthesis of pyrimidine molecules endowed with thiazolidin-4-one as new anticancer agents.	Jamia Hamdard (Hamdard University)
23906342	14	Discovery of a selective kinase inhibitor (TAK-632) targeting pan-RAF inhibition: design, synthesis, and biological evaluation of C-7-substituted 1,3-benzothiazole derivatives.	Takeda Pharmaceutical
24417566	43	Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5).	Icahn School of Medicine At Mount Sinai
24256217	177	Structure-based design of orally bioavailable 1H-pyrrolo[3,2-c]pyridine inhibitors of mitotic kinase monopolar spindle 1 (MPS1).	The Institute of Cancer Research
24286762	34	Fragment based discovery of arginine isosteres through REPLACE: towards non-ATP competitive CDK inhibitors.	University of South Carolina
23454515	66	Chemical synthesis and biological validation of immobilized protein kinase inhibitory Leucettines.	Universit£
24185375	76	Synthesis, structure-activity relationship and biological evaluation of 2,4,5-trisubstituted pyrimidine CDK inhibitors as potential anti-tumour agents.	University of Nottingham
23600925	12	Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases.	H. Lee Moffitt Cancer Center and Research Institute
23301767	154	Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities.	University of Nottingham
23249297	75	Trimeric hemibastadin congener from the marine sponge Ianthella basta.	Heinrich-Heine University
23312943	166	Optimization of highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase.	Pfizer
23312472	129	Highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase.	Pfizer
23252711	46	Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity.	University of Oxford
24900361	27	Exploring aigialomycin d and its analogues as protein kinase inhibitors for cancer targets.	TBA
20932759	100	4,5-Dihydro-1H-pyrazolo[4,3-h]quinazolines as potent and selective Polo-like kinase 1 (PLK1) inhibitors.	Nerviano Medical Sciences
16584130	95	Selectivity and potency of cyclin-dependent kinase inhibitors.	Georgetown University
15559249	55	Pharmacological inhibitors of glycogen synthase kinase 3.	The Rockefeller University
20627564	51	Activity of substituted thiophene sulfonamides against malarial and mammalian cyclin dependent protein kinases.	Walter Reed Army Institute of Research
20153204	109	Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing.	Nerviano Medical Sciences
20038108	19	Novel synthesis and structural characterization of a high-affinity paramagnetic kinase probe for the identification of non-ATP site binders by nuclear magnetic resonance.	Wyeth Research
20030405	7	Benzo[e]isoindole-1,3-diones as potential inhibitors of glycogen synthase kinase-3 (GSK-3). Synthesis, kinase inhibitory activity, zebrafish phenotype, and modeling of binding mode.	Peking University
19854650	70	Heterobiaryl purine derivatives as potent antiproliferative agents: inhibitors of cyclin dependent kinases. Part II.	Amri
19846305	86	Biaryl purine derivatives as potent antiproliferative agents: inhibitors of cyclin dependent kinases. Part I.	Amri
17850214	99	The selectivity of protein kinase inhibitors: a further update.	University of Dundee
18232649	60	Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex.	University of Oxford
15999997	85	Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase.	Serono Pharmaceutical Research Institute
12852764	20	Synthesis and in vitro characterization of 1-(4-aminofurazan-3-yl)-5-dialkylaminomethyl-1H-[1,2,3]triazole-4-carboxylic acid derivatives. A new class of selective GSK-3 inhibitors.	Novo Nordisk
15013000	31	Discovery and in vitro evaluation of potent TrkA kinase inhibitors: oxindole and aza-oxindoles.	Glaxosmithkline
22377675	44	Indeno[1,2-b]indole derivatives as a novel class of potent human protein kinase CK2 inhibitors.	Westf£Lische Wilhelms-Universit£T M£Nster
22148278	132	Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and fms-like tyrosine kinase	S Bio
22154349	123	5-(2-amino-pyrimidin-4-yl)-1H-pyrrole and 2-(2-amino-pyrimidin-4-yl)-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one derivatives as new classes of selective and orally available Polo-like kinase 1 inhibitors.	Nerviano Medical Sciences
22014550	337	Discovery of a novel class of non-ATP site DFG-out state p38 inhibitors utilizing computationally assisted virtual fragment-based drug design (vFBDD).	Ansaris
22036212	8	Synthesis of 6-(het) ary Xylocydine analogues and evaluating their inhibitory activities of CDK1 and CDK2 in vitro.	Jilin University
22000924	25	Design, synthesis and biological study of novel pyrido[2,3-d]pyrimidine as anti-proliferative CDK2 inhibitors.	National Organization For Drug Control & Research
21907583	48	CNS and antimalarial activity of synthetic meridianin and psammopemmin analogs.	University of South Florida
21723120	100	Synthesis and SAR of new pyrazolo[4,3-h]quinazoline-3-carboxamide derivatives as potent and selective MPS1 kinase inhibitors.	Nerviano Medical Sciences
20621478	37	Concise synthesis and CDK/GSK inhibitory activity of the missing 9-azapaullones.	Trinity College
21470862	110	NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor.	Nerviano Medical Sciences
21094608	74	Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 1.	Merck Research Laboratories
21094607	66	Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 2.	Merck Research Laboratories
21144757	15	Design, synthesis, and testing of an 6-O-linked series of benzimidazole based inhibitors of CDK5/p25.	Duquesne University
20965724	57	Identification of potent ITK inhibitors through focused compound library design including structural information.	Nycomed
21038853	133	4-(Pyrazol-4-yl)-pyrimidines as selective inhibitors of cyclin-dependent kinase 4/6.	Novartis Institutes For Biomedical Research
20873740	111	Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding.	Nerviano Medical Sciences
20817473	57	Thieno[3,2-c]pyrazoles: a novel class of Aurora inhibitors with favorable antitumor activity.	Nerviano Medical Sciences Oncology
20483608	139	New pyrazolo[1,5a]pyrimidines as orally active inhibitors of Lck.	Novartis Institute of Biomedical Research
20397705	208	Identification of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as a new class of orally and selective Polo-like kinase 1 inhibitors.	Nerviano Medical Sciences
20223663	100	2-Arylureidophenyl-4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)triazines as highly potent and selective ATP competitive mTOR inhibitors: optimization of human microsomal stability.	Wyeth Research
20045222	40	Design, synthesis, and biological evaluation of novel pyrimidine derivatives as CDK2 inhibitors.	National Organization For Drug Control & Research
19854645	87	Synthesis and PKCtheta inhibitory activity of a series of 5-vinyl phenyl sulfonamide-3-pyridinecarbonitriles.	Wyeth Research
20141146	234	Identification of potent pyrazolo[4,3-h]quinazoline-3-carboxamides as multi-cyclin-dependent kinase inhibitors.	Nerviano Medical Sciences
18815031	41	Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitors.	Astrazeneca
17149885	20	Profile and molecular modeling of 3-(indole-3-yl)-4-(3,4,5-trimethoxyphenyl)-1 H-pyrrole-2,5-dione (1) as a highly selective VEGF-R2/3 inhibitor.	Eberhard-Karls University
17123821	21	Design, synthesis, and antiproliferative and CDK2-cyclin a inhibitory activity of novel flavopiridol analogues.	University of Kansas
16750360	36	CA224, a non-planar analogue of fascaplysin, inhibits Cdk4 but not Cdk2 and arrests cells at G0/G1 inhibiting pRB phosphorylation.	De Montfort University
16384702	35	CDK2/cyclinA inhibitors: targeting the cyclinA recruitment site with small molecules derived from peptide leads.	Genentech
16216502	119	Scaffold oriented synthesis. Part 1: Design, preparation, and biological evaluation of thienopyrazoles as kinase inhibitors.	Abbott Laboratories
15999992	25	Synthesis and identification of [1,3,5]triazine-pyridine biheteroaryl as a novel series of potent cyclin-dependent kinase inhibitors.	Johnson & Johnson Pharmaceutical Research and Development
15566294	5	Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole.	Università
15149684	59	3-(7-Azaindolyl)-4-arylmaleimides as potent, selective inhibitors of glycogen synthase kinase-3.	Johnson & Johnson Pharmaceutical Research & Development
14505655	61	A catch-and-release strategy for the combinatorial synthesis of 4-acylamino-1,3-thiazoles as potential CDK5 inhibitors.	Pharmacia
12182847	12	Peptide inhibitors of CDK2-cyclin A that target the cyclin recruitment-site: structural variants of the C-terminal Phe.	University of Nottingham
12036347	116	Structural classification of protein kinases using 3D molecular interaction field analysis of their ligand binding sites: target family landscapes.	Aventis Pharma Deutschland
11909733	30	Beta-carbolines as specific inhibitors of cyclin-dependent kinases.	Institute of Molecular and Cell Biology
32435391	42	Optimization of Indazole-Based GSK-3 Inhibitors with Mitigated hERG Issue and	Angelini Pharma
30639897	48	Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures.	The First Affiliated Hospital of Zhengzhou University
32129996	166	Discovery and SARs of 5-Chloro-	Anhui Medical University
31846828	2	Development of selective mono or dual PROTAC degrader probe of CDK isoforms.	Sichuan University and Collaborative Innovation Center of Biotherapy
31757666	314	Discovery and optimization of heteroaryl piperazines as potent and selective PI3K? inhibitors.	Merck
30665142	41	Cink4T, a quinazolinone-based dual inhibitor of Cdk4 and tubulin polymerization, identified via ligand-based virtual screening, for efficient anticancer therapy.	De Montfort University
30755337	95	Optimization of an azetidine series as inhibitors of colony stimulating factor-1 receptor (CSF-1R) Type II to lead to the clinical candidate JTE-952.	Japan Tobacco
31382120	4	Novel dual inhibitors targeting CDK4 and VEGFR2 synergistically suppressed cancer progression and angiogenesis.	Nankai University
31098000	63	Discovery of CDK5 Inhibitors through Structure-Guided Approach.	University of South Australia
31272794	6	Discovery of novel 9H-purin derivatives as dual inhibitors of HDAC1 and CDK2.	Chongqing Medical University
31307887	64	Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma.	Genentech
30943029	59	3,5,7-Substituted Pyrazolo[4,3- d]pyrimidine Inhibitors of Cyclin-Dependent Kinases and Their Evaluation in Lymphoma Models.	Palack£
30733087	53	A review on flavones targeting serine/threonine protein kinases for potential anticancer drugs.	China Pharmaceutical University
31238183	13	Design of wogonin-inspired selective cyclin-dependent kinase 9 (CDK9) inhibitors with potent in vitro and in vivo antitumor activity.	China Pharmaceutical University
31254921	7	Discovery of novel pyrimidine-based benzothiazole derivatives as potent cyclin-dependent kinase 2 inhibitors with anticancer activity.	Southern Medical University
30565923	34	Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology.	Eberhard Karls University T£Bingen
30978559	38	Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib.	University of Padova
30543440	86	Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update.	University of South Australia Cancer Research Institute
30384048	365	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.	University of Florida
31526603	379	Structure-based rational design of staurosporine-based fluorescent probe with broad-ranging kinase affinity for kinase panel application.	Takeda Pharmaceutical
30234987	232	How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases?	Palack£
28156111	214	Highly Potent, Selective, and Orally Bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation.	University of South Australia
25368960	17	Biphenyl-4-carboxylic acid [2-(1H-indol-3-yl)-ethyl]-methylamide (CA224), a nonplanar analogue of fascaplysin, inhibits Cdk4 and tubulin polymerization: evaluation of in vitro and in vivo anticancer activity.	De Montfort University
24304238	22	8-Substituted O(6)-cyclohexylmethylguanine CDK2 inhibitors: using structure-based inhibitor design to optimize an alternative binding mode.	University of Oxford
31200237	95	Discovery of 6-(2-(dimethylamino)ethyl)-N-(5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole-6-yl)pyrimidin-2-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-amine as a highly potent cyclin-dependent kinase 4/6 inhibitor for treatment of cancer.	Shanghai Pharmaceuticals Holding
24015767	3	Drug discovery for neglected diseases: molecular target-based and phenotypic approaches.	University of Dundee
23323521	52	Optimization of non-ATP competitive CDK/cyclin groove inhibitors through REPLACE-mediated fragment assembly.	University of South Carolina
20869873	65	3D-QSAR and docking studies on pyrazolo[4,3-h]qinazoline-3-carboxamides as cyclin-dependent kinase 2 (CDK2) inhibitors.	Jinan University
30165341	72	Synthesis and SAR of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as potent and selective CDK4/6 inhibitors.	Jiangnan University
30199702	24	A ?-glucuronidase-responsive albumin-binding prodrug for potential selective kinase inhibitor-based cancer chemotherapy.	Universit£
29046238	17	1,3,5-Triazines: A promising scaffold for anticancer drugs development.	Universit£
30197029	27	Synthesis and biological evaluation of novel 5,6-dihydropyrimido[4,5-f]quinazoline derivatives as potent CDK2 inhibitors.	Jiangnan University
29985601	64	Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics.	Seoul National University
30253346	46	Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor.	Chinese Academy of Sciences
29247857	102	A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy.	Beijing Normal University
30199249	92	Introduction of a Methyl Group Curbs Metabolism of Pyrido[3,4- d]pyrimidine Monopolar Spindle 1 (MPS1) Inhibitors and Enables the Discovery of the Phase 1 Clinical Candidate N	The Institute of Cancer Research
30082069	359	ROCK inhibitors 3: Design, synthesis and structure-activity relationships of 7-azaindole-based Rho kinase (ROCK) inhibitors.	Vertex Pharmaceuticals
30026041	139	Synthesis and anticancer activity of novel bisindolylhydroxymaleimide derivatives with potent GSK-3 kinase inhibition.	University College Cork
29550093	13	Discovery of novel CDK inhibitors via scaffold hopping from CAN508.	Chinese Academy of Medical Sciences and Peking Union Medical College
29273417	26	An appraisal on synthetic and pharmaceutical perspectives of pyrazolo[4,3-d]pyrimidine scaffold.	University of Kwazulu-Natal
29894944	66	Discovery of the selective and efficacious inhibitors of FLT3 mutations.	China Pharmaceutical University
29778892	48	Structure-based design of novel quinoxaline-2-carboxylic acids and analogues as Pim-1 inhibitors.	University of Tours
30091915	19	Development of Second-Generation CDK2 Inhibitors for the Prevention of Cisplatin-Induced Hearing Loss.	TBA
30067358	79	Discovery of 3-Benzyl-1-( trans-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea Derivatives as Novel and Selective Cyclin-Dependent Kinase 12 (CDK12) Inhibitors.	Takeda Pharmaceutical
29107425	90	Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders.	Korea Institute of Science & Technology (Kist)
29259738	74	Mtb PKNA/PKNB Dual Inhibition Provides Selectivity Advantages for Inhibitor Design To Minimize Host Kinase Interactions.	Vertex Pharmaceuticals
29853332	50	Benzofuro[3,2-d]pyrimidines inspired from cercosporamide CaPkc1 inhibitor: Synthesis and evaluation of fluconazole susceptibility restoration.	Universit£
29370702	41	Discovery and Preclinical Development of IIIM-290, an Orally Active Potent Cyclin-Dependent Kinase Inhibitor.	Csir-Indian Institute of Integrative Medicine
28827110	54	Synthesis and biological evaluation of N9-cis-cyclobutylpurine derivatives for use as cyclin-dependent kinase (CDK) inhibitors.	Korea Research Institute of Chemical Technology
27721154	660	Exploration of the imidazo[1,2-b]pyridazine scaffold as a protein kinase inhibitor.	University of Paris
29144137	60	Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model.	Csir-Indian Institute of Integrative Medicine
28487075	36	N-(1H-Pyrazol-3-yl)quinazolin-4-amines as a novel class of casein kinase 1?/? inhibitors: Synthesis, biological evaluation and molecular modeling studies.	Rajiv Gandhi Proudyogiki Vishwavidyalaya
28557430	45	Identification of a Water-Soluble Indirubin Derivative as Potent Inhibitor of Insulin-like Growth Factor 1 Receptor through Structural Modification of the Parent Natural Molecule.	University of Kaiserslautern
	113	CDK2-CyclinA in CSAR_FULL_RELEASE_3JULY2012	Csar
16492568	12	Differential binding of inhibitors to active and inactive CDK2 provides insights for drug design.	Cyclacel
19827834	93	Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control.	Vertex Pharmaceuticals
19097791	44	2-(6-Phenyl-1H-indazol-3-yl)-1H-benzo[d]imidazoles: design and synthesis of a potent and isoform selective PKC-zeta inhibitor.	Pfizer
19200745	35	Design, synthesis and structure-activity relationships of 1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3beta.	Takeda Pharmaceutical
19603809	59	Identification of N,1,4,4-Tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a Potent, Orally Available Cyclin Dependent Kinase Inhibitor.	Nerviano Medical Sciences
19128055	24	Pyrazolo[1,5-a]-1,3,5-triazine as a purine bioisostere: access to potent cyclin-dependent kinase inhibitor (R)-roscovitine analogue.	Universite De Lyon
19143567	49	Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.	Astex
17098432	10	Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK).	Paradigm Pharmaceuticals
18656911	39	Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design.	Astex
17570665	19	Discovery of a potent CDK2 inhibitor with a novel binding mode, using virtual screening and initial, structure-guided lead scoping.	Vernalis (R&D)
12244092	12	Structural basis for Chk1 inhibition by UCN-01.	Glaxosmithkline
16289938	24	Identification of a buried pocket for potent and selective inhibition of Chk1: prediction and verification.	Vernalis (R&D)
16616492	3	A practical synthesis of the major 3-hydroxy-2-pyrrolidinone metabolite of a potent CDK2/cyclin A inhibitor.	Nerviano Medical Sciences
16290148	44	3-Amino-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: a new class of CDK2 inhibitors.	Nerviano Medical Sciences
16942020	12	Dissecting the determinants of cyclin-dependent kinase 2 and cyclin-dependent kinase 4 inhibitor selectivity.	University of Oxford
17064068	36	4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.	Palacky University
16325401	25	Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: protein structure-guided design and SAR.	Vernalis (R&D)
15686876	17	Structure-guided design of pyrazolo[1,5-a]pyrimidines as inhibitors of human cyclin-dependent kinase 2.	Vernalis (R&D)
15225695	64	4-Acylamino-6-arylfuro[2,3-d]pyrimidines: potent and selective glycogen synthase kinase-3 inhibitors.	Tsukuba Research Laboratories
12941317	25	Anilinopyrazole as selective CDK2 inhibitors: design, synthesis, biological evaluation, and X-ray crystallographic analysis.	Glaxosmithkline
12941333	61	6-heteroaryl-pyrazolo[3,4-b]pyridines: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3).	Glaxosmithkline
12699760	19	5-aryl-pyrazolo[3,4-b]pyridazines: potent inhibitors of glycogen synthase kinase-3 (GSK-3).	Glaxosmithkline
15341487	213	N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular efficacy.	Glaxosmithkline
11728181	188	Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis.	Glaxosmithkline
11960485	18	Structure-based design and synthesis of 2-benzylidene-benzofuran-3-ones as flavopiridol mimics.	Novartis Pharmaceuticals
15713378	72	Benzodipyrazoles: a new class of potent CDK2 inhibitors.	Nerviano Medical Sciences
15189033	48	3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding.	Pharmacia Italia
15828833	29	3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 2. Lead optimization.	Nerviano Medical Sciences
15974571	62	1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities.	Johnson & Johnson Pharmaceutical
11741480	41	A novel approach for the development of selective Cdk4 inhibitors: library design based on locations of Cdk4 specific amino acid residues.	Banyu Tsukuba Research Institute
15801830	127	Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4.	Pfizer
15993068	101	2-Aminoquinazoline inhibitors of cyclin-dependent kinases.	Naeja Pharmaceutical
15801831	94	Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6.	Pfizer
11101352	88	Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases.	Parke-Davis Pharmaceutical Research
12941338	18	Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2.	University of Newcastle
10956187	18	Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles.	University of Newcastle
12482427	36	4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2.	University of Newcastle
15239650	90	N2-substituted O6-cyclohexylmethylguanine derivatives: potent inhibitors of cyclin-dependent kinases 1 and 2.	University of Newcastle
12139449	114	Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives.	University of Newcastle